Cargando…
Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for...
Autores principales: | Strand, Vibeke, Betts, Keith A., Mittal, Manish, Song, Jinlin, Skup, Martha, Joshi, Avani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696282/ https://www.ncbi.nlm.nih.gov/pubmed/28762213 http://dx.doi.org/10.1007/s40744-017-0070-6 |
Ejemplares similares
-
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021) -
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022) -
A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)